LogicBio Therapeutics to Present at November Conferences

CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) — LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences:
10th Annual World Orphan Drug Congress. Panel and presentation in Barcelona, Spain on November 13 at 9:55 a.m. CET and 5:35 p.m. CET, respectively.Jefferies 2019 London Healthcare Conference. Presentation in London, United Kingdom on November 21 at 10:40 a.m. GMT.A live audio webcast of the Jefferies 2019 London Healthcare Conference will be available under the “Events and Presentations” section of LogicBio’s website. A replay of these presentations will become available approximately one hour after each event and will be archived for 30 days.About LogicBio Therapeutics
LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.
For more information, please visit www.logicbio.com.Contacts:Brian Luque
Associate Director, Investor Relations
Stephanie Simon
Ten Bridge Communications

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.